Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative

Table 3 Logistic regression model output of the association of retinal thickness measurements at baseline with PET status at v0 and v2 and clinical status change over 24 months

Retinal regions	PET status at v0				PET status at v2				Clinical status at v2
Retinal regions	Wald	OR	95% CI	p	Wald	OR	95% CI	p	Wald	OR	95% CI	p
Peripapillary RNFL
Total	0.69	0.98	0.94–1.03	0.39	2.76	0.97	0.94–1.01	0.10	2.38	1.06	0.98–1.14	0.12
Temporal	0.60	1.03	0.96–1.10	0.44	0.14	0.99	0.94–1.04	0.71	2.81	1.06	0.99–1.14	0.09
Superior	0.37	1.01	0.98–1.05	0.54	0.26	0.99	0.97–1.02	0.61	1.04	1.02	0.98–0.16	0.31
Nasal	1.19	0.98	0.95–1.02	0.28	1.93	0.98	0.95–1.00	0.17	0.03	1.00	0.96–1.05	0.87
Inferior	0.13	0.99	0.96–1.03	0.72	1.18	0.98	0.96–1.01	0.28	3.08	1.04	1.00–1.09	0.08
ETDRS macula
Centre	4.93	1.04	1.01–1.08	0.03*	4.98	1.03	1.00–1.06	0.03*	2.11	1.03	0.99–1.06	0.15
Inner temporal	4.88	1.06	1.01–1.12	0.03*	4.82	1.05	1.01–1.09	0.03*	1.48	1.03	0.98–1.08	0.23
Inner superior	3.93	1.05	1.01–1.10	0.047*	5.54	1.05	1.00–1.09	0.02*	1.48	1.03	0.98–1.08	0.22
Inner nasal	7.20	1.08	1.02–1.14	0.007*	8.39	1.06	1.02–1.10	0.004*	1.33	1.03	0.98–1.07	0.25
Inner inferior	4.14	1.05	1.00–1.10	0.04*	5.60	1.05	1.01–1.09	0.02*	2.34	1.04	0.99–1.09	0.13
Outer temporal	0.52	1.02	0.97–1.07	0.47	0.22	1.01	0.97–1.05	0.64	1.26	1.03	0.98–1.09	0.26
Outer superior	0.11	1.00	0.96–1.06	0.74	0.21	1.01	0.97–1.05	0.65	0.73	1.02	0.97–1.08	0.39
Outer nasal	2.47	1.04	0.99–1.08	0.12	1.70	1.02	0.99–1.06	0.19	2.60	1.04	0.99–1.08	0.11
Outer inferior	2.87	1.04	0.99–1.09	0.09	1.52	1.02	0.99–106	0.22	3.63	1.05	1.00–1.11	0.06
Macular multilayer
GCL+	2.22	1.12	0.96–1.31	0.14	1.65	1.08	0.96–1.21	0.20	0.76	1.07	0.92–1.24	0.38
RNFL	2.35	1.12	0.97–1.30	0.13	1.05	1.06	0.95–1.19	0.31	0.32	1.04	0.91–1.20	0.58

A 2-step logistic regression model was executed for each of the sixteen retinal thickness measures as predictors of PET status (+/−) at v0 and v2 and clinical status (SCD vs MCI) at v2, separately, and including age, gender, education, APOE ε4 status and OCT image quality as adjusting variables
*Statistical significance was set-up at p < 0.05
Abbreviations: APOE apolipoprotein E, CI confidence interval, ETDRS Early Treatment Diabetic Retinopathy Study, GCL ganglion cell layer, OR odds ratio, PET positron emission tomography, RNFL retinal nerve fiber layer, v0 baseline visit, v2 follow-up visit at 2 years

ISSN: 1758-9193